TY - JOUR
T1 - Combining chemistry and engineering for hepatocellular carcinoma
T2 - Nano-scale and smaller therapies
AU - Stolley, Danielle L.
AU - Crouch, Anna Colleen
AU - Özkan, Aliçan
AU - Seeley, Erin H.
AU - Whitley, Elizabeth McRae
AU - Rylander, Marissa Nichole
AU - Cressman, Erik N.K.
N1 - Funding Information:
This work was funded by NIH 1R01CA201127-01A1, MD Anderson Cancer Center Institutional Research Grant program, NIH CCSG P30 CA016672, The Cancer Prevention Research Institute of Texas (CPRIT) grants RR160005 and RP190617, and The James B. and Lois R. Archer Foundation, the E.L. Wiegand Foundation, and the J.S. Dunn Foundation.
Funding Information:
Funding: This work was funded by NIH 1R01CA201127-01A1, MD Anderson Cancer Center Institutional Research Grant program, NIH CCSG P30 CA016672, The Cancer Prevention Research Institute of Texas (CPRIT) grants RR160005 and RP190617, and The James B. and Lois R. Archer Foundation, the E.L. Wiegand Foundation, and the J.S. Dunn Foundation.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/12
Y1 - 2020/12
N2 - Primary liver cancer, or hepatocellular carcinoma (HCC), is a major worldwide cause of death from carcinoma. Most patients are not candidates for surgery and medical therapies, including new immunotherapies, have not shown major improvements since the modest benefit seen with the introduction of sorafenib over a decade ago. Locoregional therapies for intermediate stage disease are not curative but provide some benefit. However, upon close scrutiny, there is still residual disease in most cases. We review the current status for treatment of intermediate stage disease, summarize the literature on correlative histopathology, and discuss emerging methods at micro-, nano-, and pico-scales to improve therapy. These include transarterial hyperthermia methods and thermoembolization, along with microfluidics model systems and new applications of mass spectrometry imaging for label-free analysis of pharmacokinetics and pharmacodynamics.
AB - Primary liver cancer, or hepatocellular carcinoma (HCC), is a major worldwide cause of death from carcinoma. Most patients are not candidates for surgery and medical therapies, including new immunotherapies, have not shown major improvements since the modest benefit seen with the introduction of sorafenib over a decade ago. Locoregional therapies for intermediate stage disease are not curative but provide some benefit. However, upon close scrutiny, there is still residual disease in most cases. We review the current status for treatment of intermediate stage disease, summarize the literature on correlative histopathology, and discuss emerging methods at micro-, nano-, and pico-scales to improve therapy. These include transarterial hyperthermia methods and thermoembolization, along with microfluidics model systems and new applications of mass spectrometry imaging for label-free analysis of pharmacokinetics and pharmacodynamics.
KW - Ablation
KW - Cirrhosis
KW - Hepatocellular carcinoma
KW - Hyperthermia
KW - Mass spectrometry imaging
KW - Microfluidics
KW - Transarterial chemoembolization
UR - http://www.scopus.com/inward/record.url?scp=85098191517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098191517&partnerID=8YFLogxK
U2 - 10.3390/pharmaceutics12121243
DO - 10.3390/pharmaceutics12121243
M3 - Review article
C2 - 33419304
AN - SCOPUS:85098191517
SN - 1999-4923
VL - 12
SP - 1
EP - 18
JO - Pharmaceutics
JF - Pharmaceutics
IS - 12
M1 - 1243
ER -